A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC)
Latest Information Update: 14 Aug 2024
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HCC-TACE study
- 17 Aug 2023 Status changed from recruiting to completed.
- 07 Jun 2022 Results (n=13) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium